Novartis and the Bill has announced its collaboration with Melinda Gates Foundation to discover and develop an accessible in vivo gene therapy, thus a new method of gene therapy to cure Sickle Cell Disease (SCD).
A press release issued by the Sickle Cell Foundation of Ghana indicated that the agreement with the foundation will provide funding support for the discovery and development of a single-administration.
The release added that the Pharmaceutical company will provide in-kind support and access to its suite of technologies and resources.
“Novartis will prioritize addressing access and distribution hurdles posed by limited healthcare infrastructure in low- and middle-income countries and the funding agreement includes specific provisions to support global access to any resulting innovations.”
"The agreement would further build on the Novartis commitment to improve the lives of patients with sickle cell disease through the development of new treatments, including crizanlizumab, strategic partnerships with government and non-government organizations, and support for such interventions as newborn screenings and the distribution of existing drugs, the statement disclosed.
Hematologist and President of the Novartis Institutes for BioMedical Research (NIBR), Jay Bradner, said the Pharmaceutical Company is “thrilled to have the support of the Bill & Melinda Gates Foundation in addressing this global unmet medical need.”
According to the statement, Novartis is developing the new method of gene therapy, to alleviate SCD patients from staying long in hospitals, adding that the new method is simpler than the current methods of gene therapy.
“Novartis envisions developing an accessible in vivo gene therapy for SCD that could potentially be administered once, directly to the patient, without the need to modify the cells in a lab. This would have the advantage of mitigating the need for long or repeated hospital stays or specialized lab infrastructure."
Latest Stories
-
Sports facilities are better managed by institutions – UG Sports Director on maintenance of Legon stadium
20 mins -
Ghanaian businesses must align vision with strategy to mitigate ESG Risks – KPMG
31 mins -
MTN achieves 30% localisation of Scancom PLC
31 mins -
Attorney-General: Some lawyers sacrifice ethics for ‘cheap’ political gains
43 mins -
Bond market: Volume up by 12.45% to GH¢746m
44 mins -
Cedi records year-to-date loss of nearly 29%; one dollar going for GH¢17.10
52 mins -
‘Our priorities are wrong in Ghana’ – UG Sports Director on sports development
52 mins -
The Fourth Estate’s investigative report wins 2nd place at 2024 AIJC
1 hour -
GPL: Our fans spur us on – GoldStars head coach Frimpong Manso on unbeaten run
2 hours -
Plantain chips are breaking hearts in Africa
2 hours -
61 new architects acquire state license to practice in Ghana
2 hours -
Masloc CEO honoured as capacity building Shero of the Year
3 hours -
MPs’ Repeated Attempts to Sue the Speaker: Unintended Consequences for the 2024 Elections?
3 hours -
Today’s front pages: Tuesday, November 5, 2024
3 hours -
Galamsey: Investigation into attack on Joy News’ Erastus Asare and colleagues already growing cold
3 hours